Tanezumab

Monoclonal antibody

Also known as PF-04383119

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2021-10), on a safety finding

Tanezumab (PF-04383119) was Pfizer's anti-NGF monoclonal antibody, co-developed with Eli Lilly. Lilly's Q3 2021 sales and earnings release states that in October 2021 both companies discontinued the entire global clinical development programme after the FDA Complete Response Letter and the CHMP negative opinion in osteoarthritis; the EMA's Raylumis refusal page records the 2021-09-16 opinion and the risk of rapid progressive osteoarthritis. The diabetic peripheral neuropathic pain studies (for example NCT01087203) had already been terminated years earlier, and the stop is programme-wide. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (20)
Other / comorbidity
NCT02609828 · Pfizer
2015-10-28 – 2021-06-25 · Bone Metastasis, Cancer Pain
What this study did
NCT03031938 · Pfizer
2017-11-03 – 2020-06-04 · Osteoarthritis, Cancer Pain, Recurrent Low Back Pain
What this study did
NCT02674386 · Pfizer
2016-08-23 – 2019-07-15 · Osteoarthritis
What this study did
NCT02725411 · Pfizer
2016-05-26 – 2019-06-11 · Low Back Pain
What this study did
NCT02528188 · Pfizer
2015-07-21 – 2019-02-27 · Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
What this study did
NCT02528253 · Pfizer
2015-08-18 – 2018-12-20 · Low Back Pain
What this study did
NCT02709486 · Pfizer
2016-03-02 – 2018-11-14 · Osteoarthritis, Hip, Osteoarthritis, Knee
What this study did
NCT02697773 · Pfizer
2016-01-21 – 2018-05-14 · Osteoarthritis, Knee, Osteoarthritis, Hip
What this study did
NCT00809783 · Pfizer
2009-02-06 – 2011-06-23 · Osteoarthritis
What this study did
NCT01089725 · Pfizer
2010-03-30 – 2011-02-18 · Osteoarthritis, Arthritis, Pain
What this study did
NCT00985621 · Pfizer
2009-10-30 – 2011-02-04 · Osteoarthritis
What this study did
NCT00864097 · Pfizer
2009-08-11 – 2010-11-24 · Osteoarthritis
What this study did
NCT00863772 · Pfizer
2009-05-18 – 2010-11-16 · Osteoarthritis
What this study did
NCT00960804 · Pfizer
2010-02-15 – 2010-11-11 · Osteoarthritis
What this study did
NCT01127893 · Pfizer
2010-06-15 – 2010-09-29 · Osteoarthritis
What this study did
NCT00830063 · Pfizer
2009-05-05 – 2010-08-31 · Arthritis, Osteoarthritis
What this study did
NCT00863304 · Pfizer
2009-06-09 – 2010-08-16 · Osteoarthritis
What this study did
NCT00744471 · Pfizer
2008-11-17 – 2010-08-13 · Arthritis, Osteoarthritis, Osteoarthritis, Hip
What this study did
NCT00733902 · Pfizer
2008-09-15 – 2010-01-14 · Arthritis, Osteoarthritis
What this study did
Phase 2 (15)
Other / comorbidity
NCT04163419 · Massachusetts General Hospital
2020-04-30 – 2024-09-30 · Schwannomatosis, Pain
What this study did
NCT00545129 · Pfizer
2009-04-29 – 2012-02-07 · Neoplasm Metastasis, Palliative Care
What this study did
NCT01087203 · Pfizer
2010-03-30 – 2011-07-06 · Diabetic Peripheral Neuropathy
What this study did
NCT00924664 · Pfizer
2009-08-20 – 2011-06-22 · Low Back Pain
What this study did
NCT01146561 · Pfizer
2010-10-13 – 2011-03-22 · Chronic Pancreatitis
What this study did
NCT00994890 · Pfizer
2009-11-17 – 2011-03-01 · Osteoarthritis, Knee, Osteoarthritis, Hip
What this study did
NCT00876187 · Pfizer
2009-06-15 – 2011-02-01 · Low Back Pain
What this study did
NCT00999518 · Pfizer
2010-01-22 – 2011-01-21 · Cystitis, Interstitial
What this study did
NCT00784693 · Pfizer
2008-12-18 – 2010-04-05 · Endometriosis
What this study did
NCT00826514 · Pfizer
2009-03-25 – 2010-03-17 · Chronic Prostatitis With Chronic Pelvic Pain Syndrome
What this study did
NCT00669409 · Pfizer
2008-06-06 – 2009-12-25 · Osteoarthritis, Knee
What this study did
NCT00601484 · Pfizer
2008-03-17 – 2009-04-15 · Cystitis, Interstitial
What this study did
NCT00584870 · Pfizer
2007-07-05 – 2008-09-02 · Low Back Pain
What this study did
NCT00399490 · Pfizer
2006-09-15 – 2008-02-11 · Osteoarthritis, OA Knee Pain, Arthritis
What this study did
NCT00394563 · Pfizer
2006-03 – 2007-10 · Osteoarthritis
What this study did
Phase 1 (2)
Other / comorbidity
NCT01030640 · Pfizer
2009-12 – 2010-09 · Osteoarthritis Pain, Chronic Low Back Pain, Pain Due to Interstitial Cystitis
What this study did
NCT00788294 · Pfizer
2008-11 – 2009-06 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Diabetic Peripheral Neuropathic Pain: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tanezumab: this drugDiscontinuedMonoclonal antibodyNerve growth factor (NGF)not yet gradedNo reviewed efficacy summary in this indication
Capsaicin (Qutenza)ApprovedSmall moleculeTRPV1 (transient receptor potential vanilloid 1) channelReliable signal
NCT01533428: Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8 (Baseline to between Weeks 2 to 8): Capsaicin 8% -27.44% (Standard Deviation 26.79) vs Placebo -20.85% (Standard Deviation 28.92)
NCT01478607: Norfolk QOL-DN total score change from baseline to end of study: 30 min capsaicin + SOC -27.6% (mean difference vs SOC alone -20.9, 90% CI -31.7 to -10.1); 60 min capsaicin + SOC -32.8% (mean difference vs SOC alone -26.1, 90% CI -36.8 to -15.4); SOC alone -6.7%.
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)Partial signal
NCT01179672: Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score (Baseline, 12 weeks): Duloxetine -2.4 units on a scale (Standard Error 0.14) vs Placebo -1.97 units on a scale (Standard Error 0.14)
NCT00408993: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score (Baseline and 12 weeks): Duloxetine -2.69 units on a scale (Standard Error 0.19) vs Placebo -2.31 units on a scale (Standard Error 0.18) missed
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signalNo reviewed efficacy summary in this indication
TapentadolApprovedSmall moleculeMu-opioid receptor and norepinephrine transporter (NET)Reliable signal
NCT01041859: Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12 (Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)): DB Tapentadol ER 0.28 units on a scale (Standard Deviation 2.04) vs DB Placebo 1.3 units on a scale (Standard Deviation 2.43)
NCT00455520: Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12 (Baseline and 12 weeks): Tapentadol ER -0.1 scores on a scale (Standard Deviation 1.69) vs Placebo 1.3 scores on a scale (Standard Deviation 2.41)
CrisugabalinPhase 3Small moleculeα2δ-1 subunit of voltage-gated calcium channelsReliable signal
NCT04647773: Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001)
MirogabalinPhase 3Small moleculeα2δ-1 subunit of voltage-gated calcium channelsPartial signal
NCT04094662: Average Daily Pain Score (ADPS) change from baseline to week 14, LS mean difference vs placebo: -0.39 (95% CI: -0.74, -0.04), p = 0.0301
NCT02318706: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain (Baseline to Week 14 (post-dose 1 [15 mg QD] and post-dose 2 [20 mg and 30 mg])): DS-5565 15mg QD — Week 1: -0.39 units on a scale (Standard Deviation 0.67); Week 2: -0.6 units on a scale (Standard Deviation 0.9); Week 3: -0.78 units on a scale (Standard Deviation 1.02); Week 4: -0.87 units on a scale (Standard Deviation 1.13); Week 5: -0.97 units on a scale (Standard Deviation 1.2); Week 6: -1.01 units on a scale (Standard Deviation 1.32); Week 7: -1.06 units on a scale (Standard Deviation 1.4); Week 8: -1.07 units on a scale (Standard Deviation 1.49); Week 9: -1.13 units on a scale (Standard Deviation 1.49); Week 10: -1.19 units on a scale (Standard Deviation 1.56); Week 11: -1.23 units on a scale (Standard Deviation 1.57); Week 12: -1.24 units on a scale (Standard Deviation 1.6); Week 13: -1.27 units on a scale (Standard Deviation 1.63); Week 14: -1.34 units on a scale (Standard Deviation 1.74) | DS-5565 20 mg (10 mg BID) — Week 1: -0.4 units on a scale (Standard Deviation 0.85); Week 2: -0.72 units on a scale (Standard Deviation 1.12); Week 3: -0.84 units on a scale (Standard Deviation 1.22); Week 4: -0.94 units on a scale (Standard Deviation 1.38); Week 5: -1.06 units on a scale (Standard Deviation 1.5); Week 6: -1.13 units on a scale (Standard Deviation 1.52); Week 7: -1.13 units on a scale (Standard Deviation 1.59); Week 8: -1.26 units on a scale (Standard Deviation 1.59); Week 9: -1.27 units on a scale (Standard Deviation 1.56); Week 10: -1.33 units on a scale (Standard Deviation 1.65); Week 11: -1.36 units on a scale (Standard Deviation 1.64); Week 12: -1.36 units on a scale (Standard Deviation 1.67); Week 13: -1.43 units on a scale (Standard Deviation 1.72); Week 14: -1.47 units on a scale (Standard Deviation 1.69) | DS-5565 30 mg (15 mg BID) — Week 1: -0.6 units on a scale (Standard Deviation 1.01); Week 2: -1 units on a scale (Standard Deviation 1.27); Week 3: -1.33 units on a scale (Standard Deviation 1.49); Week 4: -1.43 units on a scale (Standard Deviation 1.63); Week 5: -1.48 units on a scale (Standard Deviation 1.68); Week 6: -1.58 units on a scale (Standard Deviation 1.73); Week 7: -1.57 units on a scale (Standard Deviation 1.72); Week 8: -1.53 units on a scale (Standard Deviation 1.79); Week 9: -1.63 units on a scale (Standard Deviation 1.76); Week 10: -1.67 units on a scale (Standard Deviation 1.83); Week 11: -1.69 units on a scale (Standard Deviation 1.8); Week 12: -1.82 units on a scale (Standard Deviation 1.84); Week 13: -1.85 units on a scale (Standard Deviation 1.93); Week 14: -1.88 units on a scale (Standard Deviation 1.88) vs Placebo — Week 1: -0.26 units on a scale (Standard Deviation 0.79); Week 2: -0.46 units on a scale (Standard Deviation 0.96); Week 3: -0.57 units on a scale (Standard Deviation 1.08); Week 4: -0.7 units on a scale (Standard Deviation 1.12); Week 5: -0.84 units on a scale (Standard Deviation 1.17); Week 6: -0.92 units on a scale (Standard Deviation 1.25); Week 7: -1.03 units on a scale (Standard Deviation 1.31); Week 8: -1.09 units on a scale (Standard Deviation 1.39); Week 9: -1.16 units on a scale (Standard Deviation 1.42); Week 10: -1.18 units on a scale (Standard Deviation 1.44); Week 11: -1.25 units on a scale (Standard Deviation 1.46); Week 12: -1.28 units on a scale (Standard Deviation 1.5); Week 13: -1.32 units on a scale (Standard Deviation 1.55); Week 14: -1.37 units on a scale (Standard Deviation 1.6)
Suzetrigine (Journavx)Phase 3Small moleculeVoltage-gated sodium channel NaV1.8Partial signal
NCT05660538: Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Pregabalin -2.09 units on a scale (95% CI -2.65--1.52) vs Suzetrigine (SUZ): Low Dose -2.18 units on a scale (95% CI -2.94--1.41) vs Suzetrigine (SUZ): Mid Dose -2.11 units on a scale (95% CI -2.67--1.55) vs Suzetrigine (SUZ): High Dose -2.26 units on a scale (95% CI -2.82--1.70)
HL-1186Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
JMKX000623Phase 2Small moleculeVoltage-gated sodium channel NaV1.8Partial signalNo reviewed efficacy summary in this indication
LY4065967Phase 2Small moleculeAngiotensin II type 2 receptor (AT2R) (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Nispomeben (NRD135S.E1)Phase 2Small molecule—Partial signal
NCT05480228: Primary (11-point NRS pain, change from baseline to week 12): NRD135S.E1 80 mg/day -1.90 (SD 2.38, n=61) vs placebo -1.94 (SD 2.27, n=61); no statistical analysis posted missed
NCT02345291: Placebo-corrected change in weekly mean daily pain intensity (11-point NRS) from run-in to Week 3 (mITT, N=86): -0.42 points for 10 mg (95% CI -1.50, 0.66; p=0.438); -0.82 points for 40 mg (95% CI -1.58, -0.07; p=0.034); -0.66 points for 150 mg (95% CI -1.35, 0.03; p=0.061). missed
PilavapadinPhase 2Small moleculeAP2-associated kinase 1 (AAK1)Partial signal
NCT06203002: Change from baseline to Week 8 in ADPS: -1.74 (10 mg), -1.70 (20 mg/10 mg titration), -1.38 (20 mg), vs -1.31 (placebo); overall primary endpoint p=0.11 (not significant, as the statistical plan required all arms to separate from placebo) missed
NCT04455633: Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating Scale (Baseline (Week 2 of the Run-in period) to Week 6): LX9211 100 mg/10 mg -1.39 score on a scale (95% CI -1.77 to -1.01) | LX9211 200 mg/20 mg -1.27 score on a scale (95% CI -1.66 to -0.88) vs Placebo -0.72 score on a scale (95% CI -1.08 to -0.36)
Pirenzepine (topical)Phase 2Small moleculeMuscarinic M1 receptor (antagonist)Partial signalFeatured results are safety only in this race
VX-993Phase 2Small moleculeVoltage-gated sodium channel NaV1.8not yet gradedNo reviewed efficacy summary in this indication
AJH-2947
Phase 1(overall)
Small molecule—Partial signalNo reviewed efficacy summary in this indication
HRS-2129Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
QR-333DiscontinuedBotanical—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.